FDA Approval Round Up: Keytruda, Opdivo Add Claims

Cancer supplements took center stage for US FDA this week, but OptiNose Inc.'s corticosteroid Xhance also took a bow.

ApproveOnKeyboard_1200x675

Merck & Co. Inc.'s Keytruda (pembrolizumab) reached double digits for FDA-approved indications, with the agency most recently backing the programmed-death receptor for the treatment of gastric cancer.

Keytruda specifically gained accelerated approval Sept. 22 for the treatment of patients with recurrent locally advanced or metastatic gastric or...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet